




The relative strengths and weaknesses of Trius Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Trius Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Trius Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 309%, being 75% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	66,687
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,234
Liabilities, Non-Current	0
Other Assets	401
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,581
Other Revenues	41,011
Property and Equipment	1,037
Research and Development	49,503
Selling, General and Administrative Expense	11,339

Output Variable	Value in 1000 USD
Assets	68,125
Liabilities	18,234
Expenses	60,842
Revenues	41,011
Stockholders Equity	49,891
Net Income	-18,250
Comprehensive Net Income	-18,250
BaseVar	94,896
ECR before Limited Liability	210%
Economic Capital Ratio	309%